10/14/2025
BioCryst to Acquire Astria Therapeutics, Expanding HAE Portfolio with Late-Stage Injectable Candidate
The acquisition adds navenibart, Astria’s late-stage, long-acting monoclonal antibody inhibitor of plasma kallikrein, currently in Phase 3 clinical development for HAE prophylaxis. Navenibart’s extended dosing schedule—every three to six months—could offer patients a more convenient alternative to existing injectable treatments.
0
2 min read